Stem Cell Therapeutics Markets - 2009 Edition

• Publication date: February 2009

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell re...

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.


With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.



While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years.



This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

• Cardiovascular disease


• Lung disease


• Arthritis


• Incontinence


• Osteoporosis


• Diabetes


• Cancer


• Orthopedics


• Infertility


• Alzheimer’s disease


• Burns (severe)


• Lupus


• Parkinson’s disease


• Liver failure


• Multiple sclerosis


• Critical limb ischemia


• Crohn's disease


• Sickle cell disease


• Multiple myeloma


• NH lymphoma


• Leukemia

• Aastrom Biosciences


• Advanced Cell Technologies


• Brainstorm Cell Therapeutics


• Celegene


• ES Cell International


• Medistem


• Neostem


• Opexa Therapeutics


• Osiris Therapeutics


• Plureon


• Regenetech


• Revivicor


• Stem Cell Sciences


• StemLifeLine


• ThermoGenesis


• VetCell Bioscience

Biotechnology Industry in the United States

CHAPTER ONE: EXECUTIVE SUMMARY

Recent Developments

Introduction

Current Stem Cell Therapies

Developmental Stem Cell Therapies

Issues in Stem Cell Research

Stem Cell Forecasts

Market Forecast

The Promise of Stem Cells in Medical Treatment

Types of Stem Cells

Embryonic Stem Cells

Important Developments in ES Cell Research

Adult Stem Cells

Important Developments

Scope and Methodology

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Cancer

Leukemia

Gene Therapy

Multiple Myeloma

Non-Hodgkin’s Lymphoma Noncancerous Diseases

Aplastic Anemia

Immunodeficiency

Lupus

Sickle Cell Disease

Other Conditions

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer’s Disease

Arthritis

Burns

Cancer

Cardiovascular Conditions

Critical Limb Ischemia

Crohn’s Disease

Diabetes

Incontinence

Infertility

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson’s Disease

Sickle Cell Disease

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Best Case

Forecasts By Disease Area

Alzheimer’s Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn’s Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson’s Disease

Sickle Cell Disease

Most Likely Case

Forecasts By Disease Area

Alzheimer’s Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn’s Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson’s Disease

Sickle Cell Disease

CHAPTER FIVE: COMPANY PROFILES

Aastrom Biosciences

Advanced Cell Technologies

Athersys

Brainstorm Cell Therapeutics

Celegene

ES Cell International

Medistem

MultiCell Technologies, Inc.

Neostem

Nephros Therapeutics, Inc.

Opexa Therapeutics

Osiris Therapeutics

Plureon

Regenetech

Revivicor

Stem Cell Sciences

ThermoGenesis

VetCell Bioscience

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007

Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020

Table 3-4: Types and Features of Urinary Incontinence, 2007

Table 3-5: Types and Causes of Male Infertility, 2007

Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007

Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer’s Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn’s Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson’s Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES

Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007